Published Date: 16 Mar 2023
In Part 1 of the Obesity Series, Katherine H. Saunders, MD, DABOM discusses ways to treat childhood obesity, including the benefits of FDA-approved drugs and Intellihealth.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma
2.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
3.
Pulled Myeloma Drug Improves Survival in Trial
4.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
5.
The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.
1.
Uncovering the Hidden Gallons: How Much Blood Is Inside the Human Body?
2.
Unlocking the Secret to Accurate ANC Calculation with This Informative Blog Post
3.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
4.
Advancing Cancer Trials: Integrating Master Protocols and Immunotherapy Guidelines
5.
Clinical Insights in Hematology in Daily Practice
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation